A practical comparison of CAR-T products approved in China (NMPA) and globally — what they target and who they treat.
China has built one of the world's most active CAR-T approval landscapes. The products below are approved by the NMPA and used in qualified Chinese hospitals.
| Brand (INN) | Target | Key Indication | Maker | First Approved* |
|---|---|---|---|---|
| 奕凯达 (Yescarta® / 阿基仑赛) | CD19 | Relapsed/refractory large B-cell lymphoma | Fosun Kite | 2021 |
| 倍诺达 (Carteyva® / 瑞基奥仑赛) | CD19 | Relapsed/refractory large B-cell lymphoma | JW Therapeutics | 2021 |
| 福可苏 (Equecabtagene / 伊基奥仑赛) | BCMA | Relapsed/refractory multiple myeloma | Innovent / IASO Bio | 2023 |
| 源瑞达 (Inaticabtagene / 纳基奥仑赛) | CD19 | Relapsed/refractory B-cell ALL (incl. pediatric) | Juven Sc (合源生物) | 2023 |
| 赛凯泽 (Zevorcabtagene / 泽沃基奥仑赛) | BCMA | Relapsed/refractory multiple myeloma | Carsgen (科济药业) | 2024 |
*Year shown is the NMPA approval year for the lead indication; additional indications and product approvals continue to be added. This table is illustrative and not exhaustive — the Chinese CAR-T pipeline grows each year.
These FDA/EMA-approved CAR-T therapies are the international reference standards and inform treatment approaches worldwide.
| Brand (INN) | Target | Representative Indications | Maker |
|---|---|---|---|
| Kymriah® (tisagenlecleucel) | CD19 | B-ALL; DLBCL; follicular lymphoma | Novartis |
| Yescarta® (axicabtagene ciloleucel) | CD19 | Large B-cell lymphoma; follicular lymphoma | Kite / Gilead |
| Tecartus® (brexucabtagene autoleucel) | CD19 | Mantle cell lymphoma; B-ALL | Kite / Gilead |
| Breyanzi® (lisocabtagene maraleucel) | CD19 | Large B-cell lymphoma | BMS |
| Abecma® (idecabtagene vicleucel) | BCMA | Relapsed/refractory multiple myeloma | BMS / 2seventy bio |
| Carvykti® (ciltacabtagene autoleucel) | BCMA | Relapsed/refractory multiple myeloma | Janssen / Legend |
CD19 CAR-Ts treat B-cell cancers (leukemias, lymphomas). BCMA CAR-Ts treat multiple myeloma. The target determines which disease a product can address.
A product may be approved for one or more specific, often relapsed/refractory, conditions. Exact eligible lines of therapy differ by country and product.
Which product and indication are actually accessible to an international patient depends on the treating hospital and local approvals. We match you to the right center.
China's CAR-T list prices are generally far below those in the US or Europe, and the total treatment episode is often a fraction of Western pricing. Growing local insurance and innovative payment schemes are improving access.
Beyond cost, China offers high-volume cellular-therapy experience, short wait times for manufacturing at established centers, and internationally trained hematology teams. Many centers provide English-speaking coordination and dedicated international patient departments.
See Partner Hospitals →